{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930336",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930336_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">Amiodarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"avatrombopag\" outputclass=\"int-heading-drug\">avatrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"avatrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/avatrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221871\">avatrombopag</xref></ph> dose with moderate CYP2C9 inhibitors in chronic immune thrombocytopenia</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Amiodarone   is predicted to   increase   the exposure to   avatrombopag .  Manufacturer advises adjust  avatrombopag  dose with moderate CYP2C9 inhibitors in chronic immune thrombocytopenia .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930337",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930337_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"avatrombopag\" outputclass=\"int-heading-drug\">avatrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"avatrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/avatrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221871\">avatrombopag</xref></ph> dose with moderate CYP2C9 inducers in chronic immune thrombocytopenia</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decrease   the exposure to   avatrombopag .  Manufacturer advises adjust  avatrombopag  dose with moderate CYP2C9 inducers in chronic immune thrombocytopenia .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930338",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930338_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">Fluconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"avatrombopag\" outputclass=\"int-heading-drug\">avatrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"avatrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/avatrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221871\">avatrombopag</xref></ph> dose with moderate CYP2C9 inhibitors in chronic immune thrombocytopenia</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluconazole   is predicted to   increase   the exposure to   avatrombopag .  Manufacturer advises adjust  avatrombopag  dose with moderate CYP2C9 inhibitors in chronic immune thrombocytopenia .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930339",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930339_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"miconazole\" outputclass=\"int-drug\">Miconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"avatrombopag\" outputclass=\"int-heading-drug\">avatrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"avatrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/avatrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221871\">avatrombopag</xref></ph> dose with moderate CYP2C9 inhibitors in chronic immune thrombocytopenia</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Miconazole   is predicted to   increase   the exposure to   avatrombopag .  Manufacturer advises adjust  avatrombopag  dose with moderate CYP2C9 inhibitors in chronic immune thrombocytopenia .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Miconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930340",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930340_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"mifepristone\" outputclass=\"int-drug\">Mifepristone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"avatrombopag\" outputclass=\"int-heading-drug\">avatrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Mifepristone   is predicted to   increase   the exposure to   avatrombopag .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mifepristone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930341",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2#bnf_i1643857930341_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"avatrombopag\" outputclass=\"int-heading-drug\">avatrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"avatrombopag\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/avatrombopag.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP221871\">avatrombopag</xref></ph> dose with moderate CYP2C9 inducers in chronic immune thrombocytopenia</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   avatrombopag .  Manufacturer advises adjust  avatrombopag  dose with moderate CYP2C9 inducers in chronic immune thrombocytopenia .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				}
			],
			"hasSearchLabel": " Avatrombopag  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/avatrombopag-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Avatrombopag </title>"
			},
			"rdfs:label": "avatrombopag"
		}
	]
}